Leaflet ONDANSETRON ACCORD 8mg injection / infusion solution in pre-filled syringe


Indicated for: nausea and vomiting

Route of administration: injectable / infusion

Substance: ondansetron (antiemetic)

ATC: A04AA01 (Alimentary tract and metabolism | Antiemetics and antinauseants | Serotonin (5ht3) antagonists)

Ondansetron is a medication used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, or surgery. It belongs to the class of 5-HT3 serotonin receptor antagonists, working by blocking these receptors in the brain and gastrointestinal tract, thereby reducing the reflex of nausea and vomiting.

Ondansetron is administered in the form of tablets, oral solution, or injections, depending on the patient's needs. It is effective in preventing both acute and delayed nausea associated with cancer treatments or postoperative care.

Common side effects include headache, constipation, fatigue, or dizziness. In rare cases, it may cause allergic reactions or heart rhythm disturbances. It is important to use ondansetron as prescribed by a healthcare provider, and patients with heart conditions or those taking other medications should inform their doctor to avoid potential interactions.

General data about ONDANSETRON ACCORD 8mg

  • Substance: ondansetron
  • Date of last drug list: 01-03-2021
  • Commercial code: W67339001
  • Concentration: 8mg
  • Pharmaceutical form: injection / infusion solution in pre-filled syringe
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
  • Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
  • Number: 13104/2020/01
  • Shelf life: 2 years-after packing for marketing;after the first opening-it is used immediately

Concentrations available for ondansetron

  • 0.08mg/ml
  • 0.16mg/ml
  • 2mg/ml
  • 2mg/ml-2ml
  • 2mg/ml-4ml
  • 4mg
  • 4mg/2ml
  • 8mg
  • 8mg/4ml